Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in ADMA Biologics, Inc., Grifols or S.A. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how ADMA Biologics, Inc., Grifols and S.A. compare based on key financial metrics to determine which better meets your investment needs.

About ADMA Biologics, Inc., Grifols and S.A.

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Latest Biotechnology and ADMA Biologics, Inc., Grifols, S.A. Stock News

As of July 30, 2026, ADMA Biologics, Inc. had a $2.0 billion market capitalization, compared to the Biotechnology median of $251.9 million. ADMA Biologics, Inc.’s stock is down 54.1% in 2026, up 1.2% in the previous five trading days and down 52.52% in the past year.

Currently, ADMA Biologics, Inc.’s price-earnings ratio is 12.7. ADMA Biologics, Inc.’s trailing 12-month revenue is $509.9 million with a 32.4% net profit margin. Year-over-year quarterly sales growth most recently was -0.3%. Analysts expect adjusted earnings to reach $0.797 per share for the current fiscal year. ADMA Biologics, Inc. does not currently pay a dividend.

As of July 30, 2026, Grifols, S.A. had a $7.1 billion market cap, putting it in the 72nd percentile of all stocks. Grifols, S.A.’s stock is down 16.8% in 2026, up 2.6% in the previous five trading days and down 21.91% in the past year.

Currently, Grifols, S.A.’s price-earnings ratio is 10.9. Grifols, S.A.’s trailing 12-month revenue is $8.5 billion with a 6.1% net profit margin. Year-over-year quarterly sales growth most recently was 9.9%. There are no analysts providing consensus earnings estimates for the current fiscal year. Grifols, S.A. currently has a 0.3% dividend yield.

How We Compare ADMA Biologics, Inc., Grifols and S.A. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at ADMA Biologics, Inc., Grifols and S.A.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

ADMA Biologics, Inc., Grifols and S.A. Growth Grades

Company	Ticker	Growth
ADMA Biologics, Inc.	ADMA	D
Grifols, S.A.	GRFS	C

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

ADMA Biologics, Inc. has a Growth Score of 37, which is Weak. Grifols, S.A. has a Growth Score of 60, which is Average.

The Growth Stock Winner: No Clear Winner

Neither ADMA Biologics, Inc., Grifols or S.A. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if ADMA Biologics, Inc., Grifols or S.A. is the better investment when it comes to sustainable growth.

ADMA Biologics, Inc., Grifols and S.A.’s Quality Grades

Company	Ticker	Quality
ADMA Biologics, Inc.	ADMA	B
Grifols, S.A.	GRFS	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

ADMA Biologics, Inc. has a Quality Score of 77, which is Strong. Grifols, S.A. has a Quality Score of 80, which is Strong.

The Quality Grade Winner: It’s a Tie!

Looking at the Quality Grade breakdown above, both ADMA Biologics, Inc., Grifols and S.A. have a grade of B. For investors who focus solely on a company’s overall quality, you will need to conduct further research into both companies to see if they are a good fit for your portfolio. As a good rule of thumb, you should always analyze multiple factors based on a wide range of metrics before choosing a company to invest in.

ADMA Biologics, Inc., Grifols and S.A.’s Momentum Grades

Company	Ticker	Momentum
ADMA Biologics, Inc.	ADMA	F
Grifols, S.A.	GRFS	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

ADMA Biologics, Inc. has a Momentum Score of 13, which is Very Weak. Grifols, S.A. has a Momentum Score of 26, which is Weak.

The Momentum Stock Winner: No Clear Winner

Neither ADMA Biologics, Inc., Grifols or S.A. has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if ADMA Biologics, Inc., Grifols or S.A. is the better investment when it comes to momentum.

Other ADMA Biologics, Inc., Grifols and S.A. Grades

In addition to Momentum, Growth and Quality, A+ Investor also provides grades for Value and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether ADMA Biologics, Inc., Grifols and S.A. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, ADMA Biologics, Inc., Grifols or S.A. Stock?

Overall, ADMA Biologics, Inc. stock has a Growth Score of 37, Momentum Score of 13 and Quality Score of 77.

Grifols, S.A. stock has a Growth Score of 60, Momentum Score of 26 and Quality Score of 80.

Comparing ADMA Biologics, Inc., Grifols and S.A.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.